Erratum: 2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). (Diabetes Care, (2020) 43, (487-493), 10.2337/dci19-0066)

Authors :: Buse, J. B.
Wexler, D. J.
Tsapas, A.
Rossing, P.
Mingrone, Geltrude
Mathieu, C.
D'Alessio, D. A.
Davies, M. J.
Mingrone G. (ORCID:0000-0003-2021-528X)
Buse, J. B.
Wexler, D. J.
Tsapas, A.
Rossing, P.
Mingrone, Geltrude
Mathieu, C.
D'Alessio, D. A.
Davies, M. J.
Mingrone G. (ORCID:0000-0003-2021-528X)
Publication Year :: 2020
Abstract: The incorrect figure legend was printed for Figure 2. The first sentence of the legend should read as follows: “Choosing glucose-lowering medication in those with indicators of high-risk or established atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or heart failure (HF).” The online version of the article (https://doi.org/10.2337/dci19-0066) has been updated to correct this error.

Tools